Call Today for a FREE Confidential Case Review - Toll-Free 24/7 (866) 920-0753

Raptiva Recall Lawyer & Lawsuit

Raptiva Recall Lawyer & Lawsuit

Raptiva (efalizumab), manufactured by Genentech USA, Inc. has been linked to the development of a serious, life-threatening brain infection called Progressive Multifocal Leukoencephalopathy (PML).

UPDATE: On April 8, 2009 Genentech (the manufacturer of Raptiva) announced a nationwide recall of Raptiva, a medication for treatment of psoriasis due to reports of patients developing progressive multifocal leukoencephalopathy (PML).

Raptiva is a prescription medication indicated for the treatment of Psoriasis. In October 2008 the U.S. Food & Drug Administration (FDA) added a “Black Box Warning” to the package labeling of Raptiva warning of the development of progressive multifocal leukoencephalopathy (PML). More recently on February 19, 2008, the FDA issued a Public Health Advisory warning doctors and patients that it had received three (3) confirmed cases of Raptiva patients developing PML. In all three cases, the patients unfortunately died from the brain infection.

What You Can Do & How We Can Help

The Schmidt Firm, PLLC is currently accepting claims in all 50 states for those who have taken Raptiva and have developed Progressive Multifocal Leukoencephalopathy (PML). If you or somebody you know has taken Raptiva and developed PML, you should contact our firm immediately for a free case consultation. Please click here to contact our Dangerous Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.

What is the problem with Raptiva?

Raptiva is a prescription medication indicated for the treatment of Psoriasis. In October 2008 the U.S. Food & Drug Administration (FDA) added a “Black Box Warning” to the package labeling of Raptiva warning of the development of progressive multifocal leukoencephalopathy (PML). More recently on February 19, 2008, the FDA issued a Public Health Advisory warning doctors and patients that it had received three (3) confirmed cases of Raptiva patients developing PML. In all three cases, the patients unfortunately died from the brain infection.

Progressive Multifocal Leukoencephalopathy (PML) is a serious, rare and fatal viral disease involving inflammation of the white matter of the brain. The following is a list of signs and symptoms related to Progressive Multifocal Leukoencephalopathy:

  • Mental deterioration
  • Vision loss
  • Speech disturbances
  • Ataxia
  • Paralysis
  • Coma
  • Seizures
  • Muscle weakness
  • Hemiparesis
  • Facial weakness
  • Dysphasia
  • Memory failure
  • Cognition failure

Side Effects of Raptiva

There are a variety of serious side effects associated with Raptiva. Our firm is pursing the following types of serious, life-threatening side effects:

  • Progressive Multifocal Leukoencephalopathy (PML)

Do I Have a Raptiva (efalizumab ) Recall Lawsuit?

The Schmidt Firm, PLLC is currently accepting Raptiva (efalizumab ) induced injury cases in all 50 states. If you or somebody you know has been injured by Raptiva, you should contact our firm immediately for a free case consultation. Please use the form below to contact our Dangerous Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.

Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us your case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.

Free Case Evaluation

The Schmidt Firm, PLLC has been recognized as one of the nation’s leading plaintiffs’ law firms and handles cases in all 50 states. We are very proud of our legal achievements, but equally self-respecting of our firm’s reputation for providing personal attention to each and every client we represent.

No matter what type of case you have, you may contact us with confidence by filling out the email contact form below or calling us directly by dialing toll free 24 hrs/day (866) 920-0753.

*
*
*